Who is sponsoring NCT04762225?

NCT04762225 is sponsored by Repertoire Immune Medicines.

What drugs are being tested in NCT04762225?

Interventions in NCT04762225: RPTR-168.

What condition does NCT04762225 study?

NCT04762225 studies Head and Neck Squamous Cell Carcinoma, Melanoma, Cervical Cancer.

Is NCT04762225 still recruiting?

NCT04762225 is currently terminated. Last updated 6 December 2022.

Last reviewed 2022-12-06 · How we verify

NCT04762225

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

RPTR-168 in Patients With Human Papillomavirus Strain 16 (HPV-16) E6/E7 Positive Tumors and Melanoma

Terminated Phase 1 Last updated 6 December 2022

What this trial tests

Phase 1 trial testing RPTR-168 in Head and Neck Squamous Cell Carcinoma in 7 participants. Terminated before completion.

Timeline

10 May 2021

Primary endpoint
14 September 2022

11 October 2022

Quick facts

Lead sponsor	Repertoire Immune Medicines
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	7
Start date	10 May 2021
Primary completion	14 September 2022
Estimated completion	11 October 2022
Sites	4 locations across United States

Drugs / interventions tested

RPTR-168 — full drug profile →

Conditions studied

Head and Neck Squamous Cell Carcinoma — all drugs for Head and Neck Squamous Cell Carcinoma →
Melanoma — all drugs for Melanoma →
Cervical Cancer — all drugs for Cervical Cancer →

Sponsor

Repertoire Immune Medicines — full company profile →

Who can join

18 and older, any sex, with Head and Neck Squamous Cell Carcinoma or Melanoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to assess the safety and tolerability of escalating doses of RPTR-168 as a monotherapy in patients with HPV-16 E6/E7 positive tumors (HNSCC, cervical) and melanoma.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Tumor-Infiltrating Lymphocyte Therapy in Melanoma: Facts to the Future.
Betof Warner A, Corrie PG, Hamid O. · · 2023 · cited 81× · PMID 36485001 · DOI 10.1158/1078-0432.ccr-22-1922
Immunotherapy Approaches in HPV-Associated Head and Neck Cancer.
Julian R, Savani M, Bauman JE. · · 2021 · cited 41× · PMID 34884999 · DOI 10.3390/cancers13235889
Human Papillomavirus-Directed Therapeutics for Human Papillomavirus-Associated Oropharyngeal Cancer.
Campbell JS, Pai SI. · · 2022 · cited 4× · PMID 36165730 · DOI 10.1097/ppo.0000000000000621

Verify or expand the search:

Other recruiting trials for Head and Neck Squamous Cell Carcinoma

Currently open trials in the same condition.

NCT06980038 — Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone i · Phase 2 · recruiting
NCT07503808 — A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types · Phase 1 · recruiting
NCT06995508 — Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial · Phase 2 · recruiting
NCT07254585 — SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma · Phase 2 · recruiting
NCT07514754 — Galenos 2 Immunonutrition in Head and Neck, Lung, and Rectal Cancer Patients · NA · recruiting

Other Repertoire Immune Medicines trials

Trials by the same sponsor.

NCT07293754 — An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT05061940 — This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Selected Solid · terminated
NCT03815682 — RPTR-147 in Patients With Selected Solid Tumors and Lymphomas · Phase 1 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04762225 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Repertoire Immune Medicines
Last refreshed: 6 December 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04762225.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing